Table 1. Mouse PAb and MAb reactions against DENV-2 virions and NS1 glycoproteins.
| 50% end-point (1/log10t50) ELISA titer (s.d.)c | |||||
| DENV-2 NS1 gp | DENV-2 Virions | ||||
| PAb/MAba | Immunogenb | NG-C | NSx | NSx | Ovalbumin |
| Mouse PAbs | DENV-2 (16681) NS1 gp | 4.50 (0.41) | 2.82 (0.22) | 2.85 (0.27) | 1.76 (0.16) |
| Mouse PAbs | DENV-2 (NGC) NS1 gp | 4.33 (0.41) | 2.68 (0.25) | 2.78 (0.29) | 1.84 (0.16) |
| Mouse PAbs | DENV-2 (NSx) NS1 gp | 4.13 (0.39) | 2.81 (0.22) | 2.65 (0.27) | 1.71 (0.18) |
| Mouse PAbs | Ovalbumin | 0.87 (0.07) | 0.80 (0.06) | 1.11 (0.12) | 4.66 (0.24) |
| Mouse PAbs | DENV-2 (NGC) infections | 3.38 (0.11) | 2.15 (0.12) | 5.25 (0.25) | 1.21 (0.12) |
| MAb 2A5.1 | DENV-2 (PR159) NS1 gp | 5.86 (0.03) | 5.81 (0.04) | 0.60 (0.02) | 0.41 (0.02) |
| MAb 2C5.1 | DENV-2 (PR159) E gp | 2.32 (0.02) | 2.13 (0.02) | 5.51 (0.03) | 0.17 (0.01) |
| MAb 2A4.1 | DENV-2 (PR159) prM gp | 2.05 (0.02) | 1.87 (0.01) | 4.36 (0.04) | 0.18 (0.01) |
Mouse monoclonal antibodies (MAbs) specific for the NS1 (2A5.1), E (2C5.1) or prM (2A4.1) glycoproteins or polyclonal antibodies (PAbs) generated against DENV-2 infections or immuno-affinity purified DENV-2 NS1 glycoproteins, and which were collected immediately prior to challenge with either the DENV-2 NG-C or NSx strains.
Immunogen as either the immuno-affinity purified NS1 glycoprotein (NS1 gp) of the DENV-2 16681, NG-C or NSx strains, ovalbumin (control protein) or repeated live DENV-2 (NG-C strain) infections.
The mean reciprocal log10 50% end-point ELISA titer (1/log10t50) and standard deviation (s.d.) of pools of mouse PAbs or MAbs, against the immuno-affinity purified NS1 glycoproteins of the DENV-2 NG-C or NSx strains, ovalbumin (control protein) or purified DENV-2 (NSx strain) virions, when detected using peroxidase-labelled goat anti-mouse IgG (H&L) second antibodies. Mouse PAbs which had higher ELISA titers against the DENV-2 virions of the NSx strain than its NS1 glycoprotein are underlined.